查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424450

全球莫基奥症候群治疗药物市场：按产品类型、治疗方法、按疾病类型、按分销管道、按地区

Global Morquio Syndrome Drug Market, By Product Type, By Treatment, By Disease Type, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球莫基奥症候群（MPS-IV）治疗市场规模预计将从 2024 年的 190 万美元增加到 2031 年的 430 万美元，预测期内年复合成长率(CAGR)为 12.4%。

报告范围 报告详情
基准年 2023年 2023/2024年市场规模 190万美元
实际资料 2019年至2023年 预测期 2024-2031
预测期2023/2024~2030/2031年复合成长率： 12.40% 2030/2031价值预测 430万美元
图 1. Morquio 症候群 (MPS-IV) 治疗药物的全球市场占有率(%)，按地区划分，2024 年
全球莫基奥症候群药物市场-IMG1

IV 型黏多醣贮积症 (MPS IV) 是一种罕见疾病，患者体内缺乏或没有足够的酵素来分解长链糖分子。这些分子链称为Glico（以前称为黏多醣）。它是由分解硫酸角质素和硫酸软骨素的 N-乙酰半乳糖胺-6-硫酸酯酶 (GALNS) 或 β-半乳糖苷酶缺乏引起的。当这些糖在细胞、组织和器官中累积时，会导致骨骼发育不良、身材矮小、关节异常、呼吸道疾病（如气道阻塞）、心臟病、听力损失和角膜混浊。 MPS-IV 无法治疗方法，治疗方法仅限于症状治疗。然而，酵素替代疗法（ERT）和造血干细胞移植（HSCT）在控制症状和改善患者生活品质方面取得了一些成功。 MPS IV 是一种遗传疾病。也就是说，它通常在家庭内部传承。如果父母双方都有与 MPS IV 相关的故障基因，他们的孩子各有 25%（四分之一）的机会患上 MPS IV。这称为体染色体隐性遗传。

市场动态：

全球莫基奥症候群（MPS-IV）治疗市场的主要驱动力是这种罕见遗传疾病的盛行率不断上升、人们对可用治疗方案的认识不断提高以及具有新颖作用机制的强大管道药物。然而，由于它是一种罕见疾病，治疗成本高昂，以及与重组酶生产相关的问题是限制市场成长的因素。然而，改进治疗方法的开拓、罕见疾病研究经费的增加以及提供市场独占性的孤儿药称号正在为该市场的主要参与企业提供利润丰厚的机会。

本研究的主要特点

  • 本报告对全球莫基奥症候群（MPS-IV）治疗药物市场进行了详细分析，并以2023年为基准年估计了预测期（2024-2031年）的市场规模和年复合成长率（CAGR% ）。它被出版了。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 本报告根据公司亮点、产品系列、关键产品亮点、财务绩效和策略等参数，提供了全球莫基奥症候群 (MPS-IV) 治疗市场中主要公司的概况。
  • 该报告的见解使行销人员和经营团队负责人就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
  • 全球莫基奥症候群 (MPS-IV) 治疗市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于分析全球莫基奥症候群（MPS-IV）治疗药物市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 加强宣传活动力度
    • 缺乏熟练的医疗专业人员
    • 医疗费用增加
  • 监管场景
  • PEST分析
  • 波特的分析
  • 产品发表会
  • 合併、收购和合作

第四章全球 Morquio 症候群 (MPS-IV) 药品市场 - 冠状冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球莫基奥症候群（MPS-IV）药品市场，依产品类型，2019-2031

  • 介绍
  • 2024年及2031年市场占有率分析（%）
  • 与前一年同期比较成长分析，2020-2031
  • 细分市场趋势
  • 固态剂型
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 药片
  • 胶囊
  • 液体剂型
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 注射
  • 其他的

第 6 章 全球 Morquio 症候群 (MPS-IV) 药物市场，依治疗方法，2019-2031

  • 介绍
  • 2024年及2031年市场占有率分析（%）
  • 与前一年同期比较成长分析，2020-2031
  • 细分市场趋势
  • 酵素替代疗法
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 造血干细胞治疗
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 基因治疗
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 其他的
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率

第 7 章 2019-2031 年全球 Morquio 症候群 (MPS-IV) 药物市场（依疾病类型）

  • 介绍
  • 2024年及2031年市场占有率分析（%）
  • 与前一年同期比较成长分析，2020-2031
  • 细分市场趋势
  • 莫尔基奥A
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 莫尔基奥B
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率

第 8 章全球 Morquio 症候群 (MPS-IV) 药品市场（依通路），2019-2031 年

  • 介绍
  • 2024年及2031年市场占有率分析（%）
  • 与前一年同期比较成长分析，2020-2031
  • 细分市场趋势
  • 医院药房
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 网路药房
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率
  • 零售药房
  • 介绍
  • 2019-2031年市场规模及预测、与前一年同期比较成长率

第9章2019-2031年全球莫基奥症候群（MPS-IV）药物市场（按地区）

  • 介绍
  • 2024 年及 2031 年按地区分類的市场占有率分析 (%)
  • 2020-2031与前一年同期比较成长分析（按地区）
  • 各国的趋势
  • 北美洲
  • 介绍
  • 按产品类型分類的市场规模和预测，与前一年同期比较成长率，2019-2031
  • 市场规模和以治疗方法预测，与前一年同期比较成长率，2019-2031
  • 2019-2031 年市场规模与疾病类型预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及通路预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及各国预测、与前一年同期比较成长率
  • 美国
  • 加拿大
  • 欧洲
  • 介绍
  • 按产品类型分類的市场规模和预测，与前一年同期比较成长率，2019-2031
  • 市场规模和以治疗方法预测，与前一年同期比较成长率，2019-2031
  • 2019-2031 年市场规模与疾病类型预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及通路预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及各国预测、与前一年同期比较成长率
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 介绍
  • 按产品类型分類的市场规模和预测，与前一年同期比较成长率，2019-2031
  • 市场规模和以治疗方法预测，与前一年同期比较成长率，2019-2031
  • 2019-2031 年市场规模与疾病类型预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及通路预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及各国预测、与前一年同期比较成长率
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
  • 拉丁美洲
  • 介绍
  • 按产品类型分類的市场规模和预测，与前一年同期比较成长率，2019-2031
  • 市场规模和以治疗方法预测，与前一年同期比较成长率，2019-2031
  • 2019-2031 年市场规模与疾病类型预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及通路预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及各国预测、与前一年同期比较成长率
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 介绍
  • 按产品类型分類的市场规模和预测，与前一年同期比较成长率，2019-2031
  • 市场规模和以治疗方法预测，与前一年同期比较成长率，2019-2031
  • 2019-2031 年市场规模与疾病类型预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及通路预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及各国预测、与前一年同期比较成长率
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 介绍
  • 按产品类型分類的市场规模和预测，与前一年同期比较成长率，2019-2031
  • 市场规模和以治疗方法预测，与前一年同期比较成长率，2019-2031
  • 2019-2031 年市场规模与疾病类型预测、与前一年同期比较成长率
  • 2019-2031 年市场规模及通路预测、与前一年同期比较成长率
  • 2019-2031年按国家/地区与前一年同期比较成长率
  • 北非
  • 中部非洲
  • 南非

第10章竞争形势

  • 公司简介
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited.
  • Pfizer Inc.
  • Sanofi
  • Novo Nordisk A/S
  • Concert Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals Inc.
  • Novartis AG
  • Amgen Inc.
  • Sangamo Therapeutics
  • JCR Pharmaceuticals Co., Ltd.

第11章 章节

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6563

Global morquio syndrome (MPS-IV) drug market size is expected to reach US$ 4.3 Mn by 2031 from US$ 1.9 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 12.4% during the forecast period.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 1.9 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024-2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 12.40% 2030/2031 Value Projection: US$ 4.3 Mn
Figure 1. Global Morquio Syndrome (MPS-IV) Drug Market Share (%), By Region, 2024
Global Morquio Syndrome Drug Market - IMG1

Mucopolysaccharidosis type IV (MPS IV) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of sugar molecules. These chains of molecules are called glycosaminoglycans (formerly called mucopolysaccharides). It is caused by a deficiency in the enzymes N-acetylgalactosamine-6-sulfatase (GALNS) or beta-galactosidase which is responsible for breaking down keratan sulfate and chondroitin sulfate. The accumulation of these sugars in cells, tissues, and organs can lead to skeletal dysplasia, short stature, joint abnormalities, and respiratory issues like airway obstruction, heart defects, hearing loss, and corneal opacity. There is no cure for MPS-IV and the treatment options are limited to symptom management. However, enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) have shown some success in management of symptoms and improvement in quality of life for patients. MPS IV is an inherited disorder. This means, it is typically passed down through families. If both parents carry a nonworking copy of a gene that is related to this condition, each of their children has a 25% (1 in 4) chance of developing the disease. This is called an autosomal recessive trait.

Market Dynamics:

Global morquio syndrome (MPS-IV) drug market is primarily driven by the rising prevalence of this rare genetic disorder, growing awareness about available treatment options and strong pipeline drugs with novel mechanisms of action. However, high cost of therapy due to rarity of disease as well as challenges that are associated with production of recombinant enzymes are some of the factors restraining the market growth. Nonetheless, development of improved treatment modalities, increasing research funding for rare diseases and orphan drug designation providing market exclusivity offers lucrative opportunities for the key market players in this market.

Key features of the study:

  • This report provides in-depth analysis of the global morquio syndrome (MPS-IV) drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global morquio syndrome (MPS-IV) drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include BioMarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited., Pfizer Inc., Sanofi, Novo Nordisk A/S, Concert Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc., Novartis AG, Amgen Inc., Sangamo Therapeutics, and JCR Pharmaceuticals Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global morquio syndrome (MPS-IV) drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global morquio syndrome (MPS-IV) drug market

Detailed Segmentation:

  • Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type
    • Solid Dosage Form
    • Tablets
    • Capsules
    • Liquid Dosage Form
    • Injectable
    • Others
  • Global Morquio Syndrome (MPS-IV) Drug Market, By Treatment
    • Enzyme Replacement Therapy
    • Hematopoietic Stem Cell Therapy
    • Gene Therapy
    • Others
  • Global Morquio Syndrome (MPS-IV) Drug Market, By Disease Type
    • Morquio A
    • Morquio B
  • Global Morquio Syndrome (MPS-IV) Drug Market, By Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Global Morquio Syndrome (MPS-IV) Drug Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Top Companies in the Global Morquio Syndrome (MPS-IV) Drug Market:
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited.
    • Pfizer Inc.
    • Sanofi
    • Novo Nordisk A/S
    • Concert Pharmaceuticals, Inc.
    • Alexion Pharmaceuticals Inc.
    • Novartis AG
    • Amgen Inc.
    • Sangamo Therapeutics
    • JCR Pharmaceuticals Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Treatment
    • Market Snippet, By Disease Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Launch of Awareness Campaigns
    • Lack of skilled healthcare professionals
    • Rising healthcare expenditure
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Product Launches
  • Mergers, Acquisitions, and Collaborations

4. Global Morquio Syndrome (MPS-IV) Drug Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type, 2019-2031, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
  • Solid Dosage Form
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Tablets
  • Capsules
  • Liquid Dosage Form
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Injectable
  • Others

6. Global Morquio Syndrome (MPS-IV) Drug Market, By Treatment, 2019-2031, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
  • Enzyme Replacement Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Hematopoietic Stem Cell Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Gene Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Morquio Syndrome (MPS-IV) Drug Market, By Disease Type, 2019-2031, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
  • Morquio A
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Morquio B
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Morquio Syndrome (MPS-IV) Drug Market, By Distribution Channel, 2019-2031, (US$ Mn)

  • Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

9. Global Morquio Syndrome (MPS-IV) Drug Market, By Region, 2019-2031, (US$ Mn)

  • Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020 -2031
  • Country Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • U.S.
  • Canada
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profile
  • BioMarin Pharmaceutical Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Takeda Pharmaceutical Company Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Concert Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Alexion Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Sangamo Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • JCR Pharmaceuticals Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us